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Abstract
 .Objective: Polymorphonuclear leukocytes PMN , retained in the microvascular bed, can contribute to postischemic myocardial
reperfusion injury. Since a beneficial effect of ACE-inhibition on reperfusion injury has been reported, we investigated the impact of
 .cilazaprilat on PMN dependent reperfusion injury in isolated guinea pig hearts. Methods: Hearts ns5 per group were subjected to 15
 .min of ischemia. Immediately thereafter, a bolus of PMN was injected into the coronary system. External heart work EHW and total
cardiac nitric oxide release were measured. For microscopic evaluation, hearts received rhodamine 6G labelled PMN after ischemia, were
 .arrested 5 min later and further perfused with FITC dextran 0.1% . Localization of retained PMN was assessed by fluorescence
microscopy. Leukocyte activation was studied by FACS analysis of the adhesion molecule CD11b before and after coronary passage of
 .  .the PMN. The ACE-inhibitor cilazaprilat Cila, 2 mM and the NO-synthase inhibitor nitro-L-arginine NOLAG, 10 mM were used to
 .  .modulate nitric oxide formation of the heart. Results: Postischemic EHW recovered to 67"5% controls and 64"6% Cila of the
 . preischemic value. Addition of PMN severely depressed recovery of EHW 39"2% and NO release 39"6% of the preischemic
.  2value . Simultaneously, ischemia led to a substantial increase in postcapillary PMN adhesion from 21"5 to 172"27 PMNrmm
.  .  2.surface and CD11b-expression of the recovered PMN 3-fold . Cila attenuated postischemic PMN adhesion 83"52 PMNrmm and
 .  .activation of PMN, whereas it improved recovery of work performance 64"4% and NO release 65"4% in the presence of PMN.
 2.Conversely, NOLAG increased PMN adhesion 284"40 PMNrmm and myocardial injury. We conclude that ACE-inhibition prevents
leukocyte dependent reperfusion injury mainly by inhibition of postcapillary leukocyte adhesion. The effect may be mediated by NO,
given the proadhesive effect of NOLAG. q 1997 Elsevier Science B.V.
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1. Introduction
Reperfusion of an occluded coronary artery is the only
known therapeutic strategy preventing myocardial necrosis
if applied in time. Nevertheless, reperfusion itself can
induce a certain damage, i.e. reperfusion injury. Clinically
it may appear as reversible decrease of myocardial contrac-
 . w xtility stunning 1,2 , or as reversible loss of endothelial
w xfunction 3 . However, both deficits may persist in single
cases, if microcirculatory perfusion is impaired for a pro-
)  .  .Corresponding author. Tel. q49-89 5996402; Fax q49-89
5996378; E-mail u721101@sunmail.lrz-muenchen.de
longed time, as indicated by low-reflow or no-reflow
w xphenomena 4,5 .
 .Polymorphonuclear granulocytes PMN which are re-
cruited and activated in the reperfused myocardium can
w xcontribute to myocardial reperfusion injury in patients 6 ,
w xas well as in a variety of models in vivo 7–11 and in situ
w x12,13 . Two alternative mechanisms are considered rele-
vant for PMN retention in microcirculatory beds. Capillary
plugging of PMN as physical process is caused by narrow-
ing of capillary lumina andror reduced leukocyte elasticity
w x14 . On the other hand, neutrophils may selectively inter-
Time for primary review 51 days.
0008-6363r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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act with endothelial cells through adhesion molecules, as
w xdemonstrated after myocardial ischemia 15,16 . The adhe-
sion process of PMN on endothelial cells generally follows
w xa two-step pattern 17 , a slow movement of a leukocyte on
 .the endothelial cell wall rolling and subsequent firm
 .  w x.adhesion sticking for review see 18
Inhibition of the angiotensin I converting enzyme
 .ACE , which represents a widely used pharmacologic
intervention in patients with coronary artery disease, was
beneficial against myocardial reperfusion injury in several
w xdistinct models 19–23 . ACE-inhibition has been shown
to reduce bradykinin degradation, in turn stimulating nitric
w xoxide synthase 24,25 . Since NO mitigates PMN adhesion
w xin other vascular beds 26 , we wanted to investigate the
cardioprotective potential of ACE-inhibition during post-
ischemic reperfusion in an isolated heart model where the
contribution of PMN to reperfusion injury can be distin-
guished from other sources of postischemic damage. To
evaluate the effect, we assessed pre- and postischemic
myocardial and endothelial function in terms of external
heart work and endothelial nitric oxide release, respec-
tively. In addition, we performed in situ fluorescence
microscopy to characterize the precise localization and
quantity of postischemically retained PMN. To determine
the importance of NO, ACE inhibition was consistently
 .compared with a nitric oxide synthase inhibitor NOLAG
in further experiments.
2. Methods
2.1. Materials
Cilazaprilat, which was a gift of Hofmann-La Roche
 .Basel, Switzerland , was used at 2 mM. Nitro-L-arginine
 .NOLAG, Sigma Chemie, Deisenhofen, FRG was used at
 .10 mM, rhodamine 6G Sigma Chemie was used to label
PMN. Percoll for PMN separation and fluorescein isothio-
 .cyanate–dextran FITC dextran, MW 150 000 were pur-
chased from Pharmacia Biotech AB, Uppsala, Sweden.
Monoclonal antibodies against CD15 Miltenyi, Cologne,
.FRG were used for human PMN separation, whereas
CD11b analysis was performed with monoclonal antibod-
 .ies from Exalpha Boston, MA .
2.2. PMN preparation
2.2.1. Homologous
 .For in situ microscopy experiments, PMN guinea pig
w xwere isolated as previously described 27,28 . Using HES
sedimentation, Percoll separation and red cell lysis with
distilled water, a pellet of at least 95% pure, 99% viable
PMN was obtained. PMN were incubated with rhodamine
 . 6G 0.005%, 10 min , counted Coulter Counter ZM with
.Channelyzer, Coulter Electronics, King, NC, USA , and
 6 .adjusted to the required cell content per ml 10=10 rml .
2.2.2. Human
In order to study PMN activation by flow-cytometrical
surface analysis, a heterologous source of PMN was used,
because no guinea pig antibody against CD11b was avail-
able to the best of our knowledge. Human PMN were
isolated from peripheral venous blood of healthy volun-
teers by magnetic bead separation, as described elsewhere
w x29 . Briefly, purification of neutrophils from 10 ml human
 .blood EDTA 0.1% was achieved by magnetic separation
of cells previously labelled with a CD15 antibody carrying
iron microbeads Miltenyi Biotech, Bergisch Gladbach,
. FRG . Cells were analyzed by flow cytometry FACScan,
.Becton Dikinson, San Jose, CA, USA and proved to be
99% PMN. Cells were resuspended in Tyrode’s solution
 . 6pH 7.40 , counted and diluted to 10=10 cellsrml. As
established in an earlier study, the cells prepared by these
two techniques are not prestimulated and of comparable
w xreactivity 29 .
2.3. Heart preparation
The care of the animals and all experimental procedures
conform with the Guide for the Care and Use of Labora-
tory Animals. Guinea pig hearts were isolated and perfused
as previously described. Briefly, animals male, 200–250
.  .g were anesthetized Ketanest 200 mgrkg body weight
and decapitated. The hearts were arrested with cold saline
and removed quickly from the thorax. The aorta was
canulated and retrogradely perfused with a modified
Krebs–Henseleit buffer gassed with 97% O and 3% CO2 2
 .378C, pH 7.40 .
 .For microscopic evaluation Langendorff preparation
caval, azygos and pulmonary veins were ligated. Retro-
grade perfusion was maintained throughout the experiment
and in situ microscopic period.
The working heart preparation was performed, as previ-
w xously described 30 . The caval and azygos veins were
ligated. Pulmonary venous entry was used for a canula
which, in the working mode of the heart, provided or-
thograde access for the perfusate. In the perfusion appara-
tus it was possible to switch between non-working Lan-
.gendorff mode and working heart mode. External heart
work was calculated as the sum of pressure–volume work
 .developed aortic pressure=cardiac output and accelera-
w xtion work 29 .
2.4. Experimental protocols
Immediately after canulation, hearts were perfused at
 .constant aortic pressure 80 cm H O for 5 min to finish2
preparation. At this point, hearts were assigned either to
microscopic evaluation or to functional studies including
determination of external heart work, nitric oxide release
and leukocyte activation.
In experiments assessing external heart work, pressure
volume work was performed preload 12 cm H O, after-2
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 .  .Fig. 1. L1sLangendorff period 1 5 mlrmin volume constant perfusion ; L2sLangendorff period 2 5 mlrmin ; W1sWorking period 1;
W2sWorking period 2; PMNspost-ischemic application of 107 PMN.
.  .load 60 mmHg for 20 min W1, see Fig. 1A , followed by
 .10 min of constant-flow Langendorff perfusion 5 mlrmin .
 .After ischemia 15 min, 378C , hearts were initially reper-
fused in the non-working Langendorff mode 5 mlrmin,
.20 min before a second period of external heart work at
the given conditions was begun.
For microscopic evaluation, perfusion was continued at
constant coronary flow of 5 mlrmin for 30 min see Fig.
.1B . Usually, global ischemia was next imposed for 15
min, during which hearts were immersed in warm per-
 .fusate 378C, pH 7.40 . Thereafter, reperfusion was started,
again at 5 mlrmin, lasting for 5 min in all experiments.
PMN were applied when reperfusion was started and
recovered in the coronary effluent for 3 min for further
analysis. Cold cardioplegic solution was then infused to
arrest the heart. After being placed on a stage displaying
the left ventricle area to the microscope, FITC-infusion
was begun.
Most experimental series involved 10 hearts, 5 of each
used in parallel experiments for either microscopic or
functional evaluation. Time matched ‘control’ experiments
were performed without ischemia, 107 PMN being applied
after 45 min of perfusion. In the ‘ischemia’ series PMN
were infused in the first min of reperfusion after 15 min of
ischemia. In addition, one working heart group was sub-
jected to ischemia without PMN infusion. To assess the
 .role of endogenous NO, cilazaprilat 2 mmolrl and nitro-
 .L-arginine NOLAG, 10 mmolrl were added to the per-
 .fusate in order to stimulate indirectly or inhibit NO
synthase activity in experiments including ischemia.
2.4.1. Nitric oxide release
In working heart experiments, a nitric oxide sensitive,
 .microtip probe WPI, Sarasota, FL, USA was placed into
the pulmonary artery directly behind the pulmonary valve,
the tip of the NO sensor being inserted into a T-tube.
Isothermal conditions were achieved by immersing prepa-
rations in Tyrode’s solution at 378C. Validation of the
probe recording in the coronary effluent was performed
using bradykinin to generate NO by the endothelium, and
 .erythrocyte-borne hemoglobin hematocrit 5% to se-
 .quester NO data not shown . Reproducible stimulation
and suppression of the signal to zero were observed,
respectively.
Considerable variability of basal release of NO between
 .hearts during preischemic volume constant perfusion L1
was found in all groups. Comparability of volume constant
 .perfusion and working heart mode different flow rates
was achieved by calculating NO release per minute per g
dry weight of the hearts from the concentration data.
Postischemic NO release is given in percent of pre-
ischemic values.
2.4.2. Fluorescence microscopy
For the purpose of in situ microscopy hearts were
arrested by cold cardioplegic solution potassium 28
.mmolrl . Thereafter they were placed on a specially de-
signed microscopic stage holder, the surface of the left
ventricle being exposed to a microscope Ploemopak, Leitz,
. Wetzlar, FRG with a 10-fold objective L10, 0.22 Aper-
.ture, Leitz . Images were generated by a charge coupled
device camera COHU 4400, Prospective Measurements,
.San Diego, CA . To analyze vessel distribution fluorescein
 .  .isothiocyanate dextran FITC 0.1% was infused 15 mlrh
and excited by epi-illumination with a H130 mercury light
source and filtered with an I filter block Leitz, excita-2,3
.tionremission spectra: 450–490r)515 nm . The distribu-
tion of PMN was studied under a rhodamine 6G selective
N filter block Leitz, excitationremission spectra: 515–2
.560r)580 nm .
This method allowed for localization of PMN with
respect to the vascular lumen. Capillary plugging was
assessed by counting PMN in regions devoid of venules. 5
fields with an area of 1.2 mm2 each were studied per heart.
Postcapillary venular adhesion was observed in venules of
 .10–50 mm diameter small venules, ns8–10 per heart .
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Fig. 2. Example of PMN retention in reperfused epicardial vessels. Scale
bar: 100 mm. The upper panel demonstrates distribution of vessels
 .FITC–dextran 0.1% , two branches of arteriolae marked by white ar-
rows. Lower panel shows pattern of leukocyte retention. Plenty of PMN
are localized in venular vessel lumina, while no adhesion was found in
arteriolae.
In addition, venules of 50–300 mm diameter large venules,
.ns4–5 per heart were investigated. Fig. 2 demonstrates
FITC and rhodamine fluorescence of an epicardial surface
of a postischemic heart, showing substantial leukocyte
adhesion in venules, but not in arterioles.
2.4.3. Flow cytometry analysis
To further assess the degree of activation induced dur-
ing coronary passage, PMN were analyzed in a flow
cytometer FACScan, Becton Dickinson, San Jose, CA,
.  .USA using a phycoerythrin PE fluorescence-labelled
 .monoclonal CD11b-antibody Moab which bound to the
PMN epitope CD11b, part of the heterodimeric adhesion
 .molecule CD11brCD18 MAC-1 . Forwardscatter analysis
and gating of the PMN range provided analysis of a
homogeneous PMN population. Isotype controls with a
 .nonbinding, fluorescence labelled Moab anti-mouse IgG1
served to determine nonspecific binding and background
fluorescence. Activation of PMN was expressed in relation
to the basal values before coronary passage. Data analysis
of 10 000 events was performed with Lysis II software on
a Hewlett Pakard system.
2.5. Statistical methods
The results are given as mean"SEM. Statistical analy-
sis was performed with one way analysis of variance
 .ANOVA . Whenever a significant effect was obtained
with ANOVA, we performed multiple comparison tests
between the groups using Dunn’s test Sigmastat statistical
.program . Differences between groups were considered
significant for p-0.05.
3. Results
Since beneficial effects of ACE-inhibitors have been
demonstrated following myocardial hypoperfusion in vivo,
we studied the effects of cilazaprilat on PMN dependent
myocardial reperfusion injury.
3.1. Functional reperfusion injury
3.1.1. Coronary and myocardial function
At a concentration of 2 mM, cilazaprilat evoked no
 .change in coronary flow CF or coronary perfusion pres-
 .  .sure CPP preischemically Table 1 , in contrast to NO-
LAG which, at 10 mM, elevated CPP. After ischemia, CPP
first decreased during postischemic dilation, before rising
above preischemic values in all groups. Fittingly, CF in W2
was significantly suppressed vs. the preischemic value in
 .all groups Table 1 . The same tendency existed in the
presence of cilazaprilat, excluding a major hemodynamic
effect of the drug. In contrast, NOLAG blunted the postis-
chemic dilation and decreased CF in W more extensively2
than PMN alone.
Values of external heart work prior to ischemia for the
various experimental groups did not differ significantly
 .Table 1 . Application of a PMN bolus without ischemia
caused only a slight detriment of external heart work
 .Control PMN, Fig. 3 . After ischemia alone, recovery of
EHW deteriorated to 67"5% of the initial value. Is-
chemia and a PMN bolus acted synergistically, reducing
recovery of EHW to 39"6%. This level was further
 .decreased to 29"6% in the presence of NOLAG 1 mM .
If the concentration of NOLAG was increased to 10 mM,
no recovery could be measured due to ventricular fibrilla-
 .tion and pump failure. Cilazaprilat 2 mM , however,
counteracted the detrimental effects of PMN without 64"
.  .4% or in the presence of NOLAG 1 mM, 41"3% ,
whereas it did not influence the recovery of reperfused
 .hearts not confronted with PMN 65"4% recovery .
Thus, postischemic myocardial performance was related
to the absence or presence of PMN. Cilazaprilat effectively
prevented PMN-induced loss of function, NOLAG aug-
mented it.
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Fig. 3. Recovery of external heart work in Working Phase 2, given in
percent of results in Working Phase 1. Control PMNs time matched
control experiments. Ischemias15 min of warm ischemia, Ischemiaq
PMNsbolus of 5=106 PMN given with the beginning of reperfusion,
Ischemiaq NOLAGq PMNspostischemic PMN bolus in the presence
of 1 mM Nolag. Ischemiaq NOLAGqCilaq PMNspostischemic PMN
bolus in the presence of 1 mM Nolag and 2 mM cilazaprilat. Ischemiaq
Cilaq PMNspostischemic PMN bolus in the presence of cilazaprilat.
IschemiaqCilas Ischemia and reperfusion in the presence of cilazapri-
lat.
3.1.2. Studies on nitric oxide release
Release of nitric oxide is a specific feature of the
endothelium, regulating vascular resistance. We investi-
gated endothelial integrity by measuring NO release of the
whole coronary system. Isolated guinea pig hearts perform-
ing pressure–volume work prior to ischemic challenge
 .W released NO into the coronary effluent at variable,1
 .but not significantly different rates Table 1 . The concen-
tration approximated 2–3 mM. Preischemic ‘basal’ nitric
Table 2
Nitric oxide release prior to ischemia in the different experimental groups
NO release in W NO release in L1 1
 .  .nmolrminrg nmolrminrg
aIschemia 34.0"2.4 9.0"1.8
aIschemiaqPMN 23.7"9.6 7.6"3.0
aIschemiaqPMNqCila 20.3"1.9 6.0"0.1
W sWork Phase 1, L sLangendorff Phase 1,1 1
a  .p-0.05 v. value in W ns5 per group .1
oxide release in hearts perfused in the Langendorff mode
 .  .L was markedly lower than during work W , Table 2 .1 1
Surprisingly, cilazaprilat had no discernible effect on preis-
chemic NO release, as already suggested by coronary
 .hemodynamics Table 1 . Since no in situ calibration of
the NO-flow probe was possible in the presence of NO-
LAG, no quantitative data were obtained for these experi-
mental groups. In hearts receiving PMN without preceding
 .ischemia controlqPMN , the capability to form NO was
only slightly attenuated over time, the difference between
L and L amounting to 0.5 nmolrminrg results not1 2
.shown .
To correct for differences of NO release due to the
mode of perfusion, postischemic values of L or W in2 2
Fig. 4 are given in percent of the preischemic values
 .obtained in the same mode L or W . In hearts subjected1 1
to ischemia, a transient increase in NO release after 5 min
of reperfusion was displayed in most groups, which was
 .most prominent in the presence of cilazaprilat Fig. 4 .
Although the postischemic increase in NO release lasted
only a few minutes, it was during this period that PMN
application into the coronaries occurred in the present
experiments. Over the subsequent 20 min, NO release
decreased by 30% on average. The drop was found to be
most pronounced in the PMN group 46"1% of the
.preischemic value . This leukocyte-dependent effect was
prevented by cilazaprilat, whereas no effect of cilazaprilat
was detected in hearts not subjected to PMN infusion.
Table 1
Hemodynamic characterization of the experimental groups
 .EHW W1 CF1 CF2 CPP CPP CPP NO releasebasal 5 min 20 min basal
 .  .  .  .  .  .  .mJrminrg mlrmin mlrmin mmHg mmHg mmHg nmolrminrg
Control 231"21 8.0"0.6 6.7"0.3 29.5"1.3 – – –
aIschemia 182"19 9.0"0.5 7.8"0.4 27.0"1.2 26.8"2.0 35.6"4.3 9.0"1.8
a bIschemiaqPMN 236"47 8.6"1.0 5.1"1.2 35.2"3.3 34.6"3.0 45.6"3.7 7.6"3.0
aIschemiaqPMNqNOLAG 226"18 9.0"0.4 4.9"0.2 – 23.2"1.1 43.4"7.1 n.d.
aIschemiaqPMNqCilaqNOLAG 181"17 9.7"0.4 6.3"0.4 – 20.4"1.8 30.0"4.0 n.d.
aIschemiaqPMNqCila 192"33 8.4"0.6 6.3"0.5 28.0"2.3 28.0"2.3 35.7"8.3 6.0"1.8
aIschemiaqCila 185"20 8.2"0.2 6.5"0.0 27.3"0.7 26.0"1.2 34.0"4.2 5.9"0.9
 .EHW W1 sExternal heart work in working Phase 1, CF 1sCoronary flow in W1, CF2sCoronary flow in W2, CPP sCoronary perfusion pressurebasal
in Langendorff Phase 1, CPP sCPP after 5 min of reperfusion, C PP sCPP after 20 min of reperfusion. Mean"SEM.5 20
a p-0.05 v. CF1,
b p-0.05 v. CPP ,basal
n.d.snot detectable,
– snot measured.
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Fig. 4. Coronary nitric oxide release measured by an NO-flow probe
 .  .WPI in strict isothermia 378C . Values are given in percent of preis-
 .chemic level see Table 2 . Ischemias15 min of warm ischemia, PMN
sbolus of 5=106 PMN given with the beginning of reperfusion,
Cilas2 mM Cilazaprilat. §s p-0.05 v. 5 min after ischemia; as p-
0.05 v. cilazaprilat groups at the same time.
Fig. 5. Example of postischemic PMN plugging in capillaries Ischemia
. 2group . Upper Panel: FITC–fluorescence picture, 1.2 mm field. Lower
Panel: Rhodamine 6G fluorescence picture showing PMN in capillaries.
Experiments with inhibition of NO synthases NOLAG, 10
.mM displayed neither an increase after 5 min nor a
 .decrease after 20 min of reperfusion data not shown .
However, the lack of reaction of the probe after challenge
with an erythrocyte bolus suggested that no endogenous
NO formation was taking place under this condition any-
way.
In work phase 2, hearts released only about half 55"
.  .0.5% of the NO detected in W Fig. 4 . Hearts in the1
ischemia PMN group released less nitric oxide than in the
absence of PMN. Pretreatment with cilazaprilat prevented
this effect of PMN but did not restore postischemic NO
release to the preischemic level. The relative conservation
of the postischemic NO release through cilazaprilat was
not related to a higher level of NO preischemically Table
.1 .
3.2. Leukocyte adhesion and acti˝ation after ischemia
3.2.1. Capillary plugging
PMN can be trapped in the microcirculatory system
through plugging in capillaries, where the vessel diameter
is reduced to about 10 mm and less. As shown in one
 .example Fig. 5 , ischemia induced some plugging of
PMN in epicardial capillaries. This impression was con-
firmed in quantitative analysis of 5 capillary fields per
 .heart 5 hearts per group, Fig. 6 . While cilazaprilat did not
affect postischemic plugging, NOLAG further increased it.
3.2.2. Postcapillary adhesion
3.2.2.1. Small ˝enules. Postcapillary venular adhesion of
PMN was found to be 21"5 PMN per mm2 vessel
surface area in control experiments. Ischemia induced a
 .marked increase in postcapillary adhesion Fig. 7 . Cilaza-
prilat reversed this increase to a level not significantly
different from control values. NOLAG, however, further
increased the ischemia-dependent rise of postischemic ad-
Fig. 6. PMN plugging in capillaries of reperfused hearts. Controlsno
ischemia; Ischemias15 min of warm ischemia; Cilas2 mM Cilazapri-
lat, NOLAGs10 mM nitro-L-arginine. Mean"SEM. )s p-0.05 v. all
other groups.
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Fig. 7. PMN adhesion in small and large venules in reperfused hearts.
Controlsno ischemia; Ischemias15 min of warm ischemia; Ischemia
qCilas15 min of warm ischemia in the presence of 2 mM cilazaprilat,
Ischemiaq NOLAGs15 min of ischemia in the presence of 10 mM
nitro-L-arginine. Mean"SEM. ) s p-0.05 v. paired small venule quan-
tity, as p-0.05 v. Control in small venules; qs p-0.05 v. Ischemia
qCila in small venules; §s p-0.05 v. Control in big venules.
hesion to more than 13-fold the control level. Fig. 8A and
B show two representative examples of postcapillary adhe-
 .sion in small venules with either cilazaprilat Fig. 8A or
 .NOLAG Fig. 8B added to the perfusate.
3.2.2.2. Large ˝enules. Very few PMN were localized in
 2large venules of control hearts 6"1 PMN per mm
.vessel surface area . Ischemia induced a rise of PMN
adhesion in this class of venules to 37"8 PMN per mm2
surface area. Cilazaprilat slightly reduced this value 21"5
2 .PMN per mm surface area , although no significant effect
could be obtained. NOLAG, in contrast, tended to increase
postischemic PMN adhesion in the large venules to 48"9
2  .PMN per mm surface area Fig. 7 . Taken together, these
findings suggest that postcapillary adhesion rather than
capillary plugging accounts for increased coronary PMN
retention after ischemia in the present model. ACE-inhibi-
tion reduces, while NOLAG increases adhesion, indicating
an antiadhesive effect of nitric oxide.
3.2.3. Leukocyte acti˝ation
Activation of human leukocytes was further analyzed
by quantifying CD11b surface expression. As shown in
 .Fig. 9, PMN of control experiments without ischemia
displayed almost no difference in CD11b surface expres-
sion before and after coronary passage. Postischemically,
however, a 2.6 fold elevation of CD11b expression had
occurred on PMN emerging from the coronary system.
Fig. 8. Examples of postischemic PMN adhesion in small venules. Upper
Panel: FITC–fluorescence picture, 1.2 mm2 field. Lower Panel: Rho-
damine 6G fluorescence picture showing PMN in venules. A: Representa-
tive example of the IschemiaqCila group; B: Representative example of
the IschemiaqNOLAG group.
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Fig. 9. Leukocyte activation by CD11b expression FACScan, Becton
.  .Dickenson . PMN before coronary passage hatched bars and after
 .coronary passage solid bars were analyzed. as p-0.05 v. paired
pre-passage value.
When cilazaprilat was present, this increase in CD11b-as-
sociated fluorescence intensity was completely abolished,
whereas NOLAG further enhanced CD11b expression.
These findings indicate that cilazaprilat prevents activation
and subsequent postcapillary adhesion, most likely through
a nitric oxide mediated mechanism.
4. Discussion
Early implementation of ACE inhibition after myocar-
dial infarction has proven beneficial in several models
w x19–23 . In search of a possible ‘local’ action to explain
this effect, we have previously found ACE-inhibitors to
mitigate postischemic functional damage in saline-perfused
hearts via a bradykinin and, ultimately, nitric oxide medi-
w xated pathway 31 . NO, in turn, is known to mitigate
adhesion of PMN in various vascular beds. Since PMN
strongly exacerbate post-ischemic damage in the isolated
w xheart model 27,28,31 , we set out to investigate the simul-
taneous occurrence and interdependence of four phenom-
 .ena: First, the ability of an ACE inhibitor cilazaprilat to
alleviate postischemic loss of myocardial performance in-
duced by PMN, as opposed to the action of an inhibitor of
 .NO-synthase nitro-L-arginine . Second, the actual effect
of these interventions on postischemic coronary release of
nitric oxide. Third, the corresponding changes in PMN
adhesion according to specific localization in capillaries,
small venules and collecting veins. Fourth, PMN activation
during coronary passage in post-ischemic hearts in the
presence of cilazaprilat or nitro-L-arginine.
4.1. Influence of ischemia and reperfusion
As a result of ischemia and reperfusion alone, isolated
hearts suffered from compromised external heart work
 .Fig. 3 , i.e. myocardial stunning, and a general decline in
 .production of NO Fig. 4 . Both phenomena were aggra-
vated by application of PMN during reperfusion. Reactive
oxygen species play a crucial role in this type of reperfu-
w xsion injury, as shown by others 32 as well as in our
w xmodel 27,28 . Beyond an inherent detrimental effect on
cellular processes, reactive oxygen species may enhance
interactions between endothelium and PMN by externaliza-
w xtion of stored P-selectin and PAF 29,33 as well as by
activation and translocalization of the leukocyte receptor
 . w xMac-1 CD11brCD18 34 . The latter parameter was the
 .one we chose to observe Fig. 9 . Indeed, we found CD11b
expression to be markedly elevated on PMN after passage
through the coronary system of post-ischemic hearts. These
effects may explain the fast and significant rise of venular
leukocyte adhesion immediately after resumption of coro-
nary perfusion, a time at which de novo synthesis of
adhesion molecules cannot yet have taken place. We can-
not rule out a contribution of plugging leukocytes, which
 .has approximately doubled postischemically Fig. 6 , al-
though the myocardial stunning and loss of endothelial
 .NO-release after ischemia Figs. 3 and 4 fits best to the
 .steep increase of postcapillary PMN adhesion Fig. 7 .
4.2. Influence of ACE-inhibition on PMN dependent reper-
fusion injury
Several studies have shown a cardioprotective effect of
ACE-inhibition after limited ischemia in vivo and in situ
w x19–23 . However, this work for the first time presents
direct microscopic observations that ACE-inhibition by
cilazaprilat can acutely reduce ischemia-induced PMN ad-
hesion and activation in the coronary venules independent
of any coronary hemodynamic influence. In parallel exper-
iments, cilazaprilat was capable of blunting PMN depen-
 .dent loss of myocardial external heart work and endothe-
 .lial function reduced production of NO .
In the presence of the ACE-inhibitor ramiprilat,
Schoelkens and coworkers found an increase in bradykinin
concentration immediately after ischemia in isolated rat
w xhearts 35 . Decreased bradykinin degradation due to ACE
inhibition leads to a stimulation of endothelial nitric oxide
w xsynthase 31 . In this context it is important to point out
that NO may act as an antioxidant and radical scavenger,
which may interfere with the reperfusion-induced release
of oxygen free radicals and, thus, prevent subsequent
w xactivation of endothelial cells and PMN 36 . The depen-
dence on NO is made even more probable by the fact that
cilazaprilat does not exert a radical scavenging effect itself
 . w xdata not shown , in contrast to e.g. captopril 37 . With
 .the concentration of cilazaprilat used 2 mM , no effects
were seen on recovery of external heart work during
cell-free reperfusion, as opposed to findings with higher
w xconcentrations of a similar drug 24 . The negative effect
of NOLAG on myocardial recovery is counteracted by
 .cilazaprilat Fig. 3 suggesting that in fact cilazaprilat
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really does activate nitric oxide synthase. Interestingly, NO
release was maintained by cilazaprilat at a higher level
even after PMN application, i.e., the time at which adher-
ent PMN produce tissue damaging radicals and oxidants.
How does the observed impact of cilazaprilat on my-
ocardial and endothelial recovery relate to PMN retention
of the hearts? A multitude of factors is able to change the
balance of pro- and antiadhesive behaviour of coronary
w xendothelial cells, notably NO 26 . In the presence of
cilazaprilat, we observed slightly increased nitric oxide
release during early reperfusion, the period in which PMN
 .were injected Fig. 4 . Indeed, PMN, given in the early
reperfusion, adhered less in the presence of cilazaprilat
 .Fig. 7 , while, in contrast, capillary plugging was barely
 .influenced Fig. 6 . At this point, however, it cannot be
ruled out that nitric oxide formation in the presence of
cilazaprilat has additional, indirect effects inhibiting proad-
hesive mediators formed during reperfusion, e.g. endothe-
w xlin-1 38,39 .
Since NO release from the whole intact heart is a ‘net’
effect of nitric oxide production and consumption, the
local increase of NO might have been higher but, in part,
consumed by oxygen free radicals. The crucial importance
of NO for leukocyte adhesion in our model is demon-
strated by application of NOLAG, which increased adhe-
 .sion and activation of PMN Figs. 8 and 9 . NOLAG is a
nonspecific NO synthase inhibitor which affects endothe-
 .  .lial eNOS and inducible nitric oxide synthase iNOS .
However, in primary cultured endothelial cells from iso-
lated rat hearts, we could not detect iNOS by Western
 .blotting data not shown . Therefore NOLAG most likely
affects the eNOS, the same enzyme which is activated in
the presence of cilazaprilat.
5. Conclusions
In summary, we have investigated the influence of
ACE-inhibition on PMN adhesion and myocardial and
endothelial function after a PMN bolus given early in
reperfusion of isolated hearts. Cilazaprilat mitigated postis-
chemic increase in PMN adhesion, foremost in postcapil-
lary venules. Concomitantly, PMN-induced loss of exter-
nal heart work and reduction of endothelial nitric oxide
release were prevented by cilazaprilat. ACE-inhibition also
prevented activation of PMN during passage of the coro-
nary system of postischemic hearts. Inhibition of NO-syn-
thase caused the exact opposite in each case. Thus, the
protective effects of ACE inhibition may well be mediated
by the oxygen radical scavenging ability of NO and evolve
from reduced adhesion of PMN in the presence of NO.
The findings of the present study underscore the impor-
tance of leukocyte adhesion and activation after ischemia.
Pharmacological interventions aimed at reducing leukocyte
induced reperfusion injury may well benefit those patients
who already suffer from compromised myocardial contrac-
tility. Recent clinical investigations showing leukocyte ac-
tivation in man as a potential risk factor of recurrent
w xcoronary events enforce this approach 40 .
Acknowledgements
Cilazaprilat was a gift of Hofmann La Roche Basel,
.Switzerland , which also provided the WPI nitric oxide
sensor. The study was supported in part by the Friedrich-
Baur-Foundation of the University of Munich. We thank
Veronika Frei for expert technical assistance.
References
w x1 Braunwald E, Kloner RA. The stunnned myocardium: Prolonged,
postischemic ventricular dysfunction. Circulation 1982;66:1146–
1149.
w x2 Bolli R, Patel BS, Hartley CJ, Thormbvy JI, Jeroudi MO, Roberts R.
Nonuniform transmural recovery of contractile function in stunned
myocardium. Am J Physil 1989;257:H375–385.
w x3 Seccombe JF, Schaff HV. Coronary artery endothelial function after
myocardial ischemia and reperfusion. Ann Thorac Surg
1995;60:778–788.
w x4 Maes A, Van de Werf F, Nuyts J, Bormans G, Desmet W, Mortel-
mans L. Impaired myocardial tissue perfusion early after successful
thrombolysis. Impact on myocardial flow, metabolism, and function
at late follow up. Circulation 1995;92:2072–2078.
w x5 Ragosta M, Camarano G, Kaul S, Powers ER, Sarembock IJ,
Gimple LW. Microvascular integrity indicates myocellular viability
in patients with recent myocardial infarction. New insights using
myocardial contrast echocardiography, Circulation 1994;89:2562–
2569.
w x6 Sawa Y, Taniguchi K, Kadoba K, Nishimura M, Ichikawa H,
Amemiya A, Kuratani T, Matsuda H. Leukocyte depletion attenuates
reperfusion injury in patients with left ventricular hypertrophy.
Circulation 1996;93:1640–1646.
w x7 Chatelain P, Latour J-G, Tran D, De Lorgeril M, Dupras G, Bourassa
M. Neutrophil accumulation in experimental myocardial infarcts:
relation with extent of injury and effect of reperfusion. Circulation
1987;75:1083–1090.
w x8 Go LO, Murry CE, Richard VK, Weischedel GR, Jennings RB,
Reimer KA. Myocardial neutrophil accumulation during reperfusion
after reversible or irreversible ischemic injury. Am J Physiol
1988;255:H1188–1198.
w x9 Kraemer R, Mullane KM. Neutrophils delay functional recovery of
the post-hypoxic heart of the rabbit. J Pharmacol Exp Ther
1989;251:620–626.
w x10 Tanaka M, Brooks SE, Richard VJ, FitzHarris GP, Stoler RC,
Jennings RB, Arfors KE, Reimer KA. Effect of anti-CD18 antibody
on myocardial neutrophil accumulation and infarct size after is-
chemia and reperfusion in dogs. Circulation 1993;87:526–535.
w x11 Sheridan FM, Cole PG, Ramage MS. Leukocyte adhesion to the
coronary microvasculature during ischemia and reperfusion in an in
vivo canine model. Circulation 1996;63:1784–1787.
w x12 Shandelya SML, Kuppusamy P, Weisfeldt ML, Zweier JL. Evalua-
tion of the role of polymorphonuclear leukocytes on contractile
function in myocardial reperfusion injury. Circulation 1993;87:536–
546.
w x13 Smith EF III, Egan JW, Bugelski PJ, Hillegass LM, Hill DE,
Griswold DE. Temporal relation between neutrophil accumulation
and myocardial reperfusion injury. Am J Physiol 1988;255:H1060–
1068.
 at U
niversitaetsbibliothek M
uenchen on January 24, 2013
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
( )C. Kupatt et al.rCardio˝ascular Research 36 1997 386–395 395
w x14 Schmid-Schonbein G. Capillary plugging by granulocytes and the¨
no-reflow phenomenon in the microcirculation. Fed Proc
1987;46:2397–2401.
w x15 Simpson PJ, Todd RF, Fantone JC, Mickelson JK, Griffin JD,
Lucchesi BR. Reduction of experimental canine myocardial reperfu-
 .sion injury by a monoclonal antibody anti-Mo1, anti-CD11b that
inhibits leukocyte adhesion. J Clin Invest 1988;81:624–629.
w x16 Lefer DJ, Shandelya SML, Serrano CV, Becker LC, Kuppusamy P,
Zweier JL. Cardioprotective actions of a monoclonal antibody against
CD-18 in myocardial ischemia-reperfusion injury. Circulation
1993;88:1779–1787.
w x17 von Andrian UH, Chambers JD, McEvoy LM, Bargatze RF, Arfors
KE, Butcher EC. Two-step model of leukocyte-endothelial cell
interaction in inflammation: distinct roles for LECAM-1 and the
leukcyte b -integrins in vivo. Proc Natl Acad Sci USA2
1991;88:7538–7542.
w x18 Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules.
Blood 1994;84:2068–2101.
w x19 Hartman JC, Wall TM, Hullinger TG, Shebuski R. Reduction of
myocardial infarct size in rabbits by ramiprilat: reversal by the
bradykinin antagonist HOE 140. J Cardiovasc Pharmacol
1993;21:996–1003.
w x20 Di Pasquale P, Paterna S, Valenza M, Valdes L, Albano V, Trom-
bino G, Vitrano G, Cannizzaro S, Licata G, Albiero R. Effects of
captopril on myocardial protection during cardioplegia. Int J Cardiol
1993;42:225–230.
w x21 Zughaib ME, Sun JZ, Bolli R. Effect of angiotensin-converting
enzyme inhibitors on myocardial ischemiarreperfusion injury: an
overview. Basic Res Cardiol 1993;88:155–167.
w x22 Muller CAM, Opie LH, Peisach M, Pineda CA. Chronic oral
pretreatment with the angiotensin converting enzyme inhibitor, tran-
dolapril, decreases ventricular fibrillation in acute ischaemia and
reperfusion. Eur Heart J 1994;15:988–996.
w x23 Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y,
Mori H, Kosaka H, Inoue M, Hori M, Kamada T. Beneficial effects
of inhibition of angiotensin-converting enzyme on ischemic my-
ocardium during coronary hypoperfusion in dogs. Circulation
1995;92:950–961.
w x24 Massoudy P, Becker BF, Gerlach E. Bradykinin accounts for im-
proved postischemic function and decreased glutathione release of
guinea pig heart treated with the angiotensin-converting enzyme
inhibitor ramiprilat. J Cardiovasc Pharmacol 1994;23:632–639.
w x25 Tanonaka K, Kamiyama T, Takezono A, Sakai K, Takeo S. Benefi-
cial effects of angiotensin I converting enzyme inhibitor on post-
ischemic contractile function of perfused rat heart. J Mol Cell
Cardiol 1996;28:1659–1670.
w x26 Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous
modulator of leukocyte adhesion. Proc Natl Acad Sci USA
1991;88:4651–4655.
w x27 Raschke P, Becker BF, Leipert B, Schwartz LM, Zahler S, Gerlach
E. Postischemic dysfunction of the heart induced by small numbers
of neutrophils via formation of hypochlorous acid. Basic Res Cardiol
1993;88:321–339.
w x28 Kupatt C, Zahler S, Seligmann C, Massoudy P, Becker BF, Gerlach
E. Nitric oxide mitigates leukocyte adhesion and vascular leak after
myocardial ischemia. J Mol Cell Cardiol 1996;28:643–654.
w x29 Zahler S, Kowalski C, Brosig A, Kupatt C, Becker BF, Gerlach E.
The function of neutrophils isolated by a magnetic antibody cell
separation technique is not altered in comparison to a density
gradient method. J Immunol Meth 1997;200:173–179.
w x30 Raschke P, Becker BF. Adenosine and PAF dependent mechanisms
lead to myocardial reperfusion injury by neutrophils after brief
ischemia. Cardiovasc Res 1995;29:569–576.
w x31 Massoudy P, Becker BF, Gerlach E. Nitric oxide accounts for
postischemic cardioprotection resulting from angiotensin-converting
enzyme inhibition: indirect evidence for a radical scavenger effect in
isolated guinea pig heart. J Cardiovasc Pharmacol 1995;25:440–447.
w x32 Bolli R, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R,
McKay PB. Direct evidence that oxygen-derived free radicals con-
tribute to postischemic myocardial dysfunction in the intact dog.
Proc Natl Acad Sci USA 1989;86:4695–4699.
w x33 Lewis MS, Whatley RE, Cain P, McIntyre TM, Prescott SM,
Zimmerman GA. Hydrogen peroxide stimulates the synthesis of
platelet-activating factor by endothelium and induces endothelial
cell-dependent neutrophil adhesion. J Clin Invest 1988;82:2045–
2055.
w x34 Fraticelli A, Serrano CV, Bochner BS, Capogrossi MC, Zweier JL.
Hydrogen peroxide and superoxide modulate leukocyte adhesion
molecule expression and leukocyte endothelial adhesion. Biochim
Biophys Acta 1996;1310:251–259.
w x35 Baumgarten CR, Linz W, Kunkel G, Schoelkens BA, Wiemer G.
Ramiprilat increases bradykinin outflow from isolated hearts of rat.
Br J Pharmacol 1993;108:293–295.
w x36 Suematsu M, Tamatani T, Delano FA, Miyasaka M, Forrest M,
Suzuki H, Schmid-Schonbein GW. Microvascular oxidative stress
preceding leukocyte activation elicited by in vivo nitric oxide sup-
pression. Am J Physiol 1994;266:H2410–2415.
w x37 Aruoma OI, Akanmu D, Cecchini R, Halliwell B. Evaluation of the
ability of the angiotensin-converting enzyme inhibitor captorpil to
scavenge reactive oxygen species. Chem Biol Interact 1991;77:303–
314.
w x38 Hughes AK, Stricklett PK, Padilla E, Kohan DE. Effect of reactive
oxygen sepcies on endothelin-1 production by human mesangial
cells. Kidney Int 1996;49:181–189.
w x39 Brunner F, Kukovetz WR. Postischemic antiarrhythmic effects of
angiotensin-converting enyme inhibitors. Circulation 1996;94:1752–
1761.
w x40 Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith
CW. Leukocyte activation with platelet adhesion after coronary
angioplasty: a mechanism for recurrent disease. J Am Coll Cardiol
1996;28:345–353.
 at U
niversitaetsbibliothek M
uenchen on January 24, 2013
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
